Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.
Tershakovec
Andrew M
AM
Merck Research Laboratories, Merck & Co., Inc., Upper Gwynedd, Pennsylvania, USA. andrew_tershakovec@merck.com
Keane
William F
WF
Zhang
Zhongxin
Z
Lyle
Paulette A
PA
Appel
Gerald B
GB
McGill
Janet B
JB
Parving
Hans-Henrik
HH
Cooper
Mark E
ME
Shahinfar
Shahnaz
S
Brenner
Barry M
BM
D000419:Albuminuria / Q000378:metabolism; D008078:Cholesterol, LDL / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000378:metabolism; D019808:Losartan / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D008078:Cholesterol, LDL; D019808:Losartan